全球首家私营脐带血库运营商国际低温细胞公司（Cryo-Cell International, NYSE American：CCEL）于7月15日披露截至2025年5月31日的第二财季业绩。财报显示，当季实现总营收790万美元，较2024财年同期的800万美元微降1%。
从收入构成来看，本季度处理及储存费收入达787万美元，公共库存储业务贡献4.3万美元，产品销售收入为1.4万美元。对比上年同期，三项收入分别为797万美元、4.1万美元和3.6万美元。
盈利指标呈现下行态势：季度净利润录得35.6万美元，较上年同期65.6万美元骤降45.7%；基本和稀释后每股收益报0.04美元，同比减少0.04美元。值得关注的是，产品销售收入同比下滑超六成，成为拖累整体业绩的主要因素。
本次财报未提供未来业绩指引。公司作为干细胞储存行业先行者，其业务结构调整与新产品管线进展将持续影响后续表现。投资者需密切关注其在高毛利增值服务领域的突破情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.